Stay tuned for our LIVE OncLive News Network coverage straight from the #ASH18 conference floor! 

Dr. Giralt on Mucoadhesive Clonidine in Head and Neck Cancer

Jordi Giralt, MD, PhD
Published: Wednesday, Aug 26, 2015



Jordi Giralt, MD, PhD, pathology, radiology, oncology, University Hospital Vall d'Hebron, discusses a study that examined mucoadhesive clonidine (Clonidine Lauriad) in the prevention of severe radiomucositis in patients with head and neck cancer.

Oral mucositis is a frequent side effect of chemoradiotherapy in patients with head and neck cancer. The randomized phase II study examined the efficacy of mucoadhesive clonidine against oral mucositis. Mucoadhesive clonidine has demonstrated anti-inflammatory efficacy in earlier studies, Giralt explains.

The double-blind study compared arms of mucoadhesive clonidine at 50μg, 100 μg, and placebo. The primary endpoint was the incidence of oral mucositis, Giralt says. Data showed that mucoadhesive clonidine reduced the incidence of oral mucositis by 20%.



Jordi Giralt, MD, PhD, pathology, radiology, oncology, University Hospital Vall d'Hebron, discusses a study that examined mucoadhesive clonidine (Clonidine Lauriad) in the prevention of severe radiomucositis in patients with head and neck cancer.

Oral mucositis is a frequent side effect of chemoradiotherapy in patients with head and neck cancer. The randomized phase II study examined the efficacy of mucoadhesive clonidine against oral mucositis. Mucoadhesive clonidine has demonstrated anti-inflammatory efficacy in earlier studies, Giralt explains.

The double-blind study compared arms of mucoadhesive clonidine at 50μg, 100 μg, and placebo. The primary endpoint was the incidence of oral mucositis, Giralt says. Data showed that mucoadhesive clonidine reduced the incidence of oral mucositis by 20%.


View Conference Coverage
Online CME Activities
TitleExpiration DateCME Credits
Community Practice Connections™: Oncology Best Practice™ Decision Points in Advanced NSCLC: Assessing Treatment Options Beyond Disease ProgressionNov 30, 20181.0
Community Practice Connections™: Precision Medicine for Community Oncologists: Assessing the Role of Tumor-Testing Technologies in Cancer CareNov 30, 20181.0
Publication Bottom Border
Border Publication
x